Joseph Sliman - Concepedia

Author

Joseph Sliman

Synthetic Biologics (United States)

Also Known As

Joseph A. Sliman, Joseph Sliman

Publications

643

Citations

H-Index

Concepts

All Affiliations

Synthetic Biologics (United States)

About

Joseph Sliman is an author at Synthetic Biologics (United States) specializing in clinical microbiology, infection control, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	191
2	Microbiology	3	3	180
3	Health Sciences	1	1	68
4	Biomolecular Engineering	1	1	68
5	Epidemiology	1	1	11

Joseph Sliman

Publications

606

Citations

H-Index

Page 1

	Year	Citations
Age-Specific Prevalence of Epstein–Barr Virus Infection Among Individuals Aged 6–19 Years in the United States and Factors Affecting Its Acquisition Henry H. Balfour, Frangiscos Sifakis, Joseph Sliman, The Journal of Infectious Diseases	2013	257
Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial John F. Kokai‐Kun, Tracey Roberts, Olivia Coughlin, The Lancet Infectious Diseases Antimicrobial SusceptibilityAntibioticsPhase 2Bβ-Lactam-treated PatientsPlacebo-controlled Trial	2019	82
Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age Elissa Malkin, Ram Yogev, Nazha Abughali, PLoS ONE	2013	80
Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection Michael Kaleko, J. Andrew Bristol, Steven Hubert, Anaerobe DysbiosisAntibiotic-mediated DamageComplex EcosystemOral Beta-lactamase TreatmentDrug Resistance	2016	68
The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies John F. Kokai‐Kun, Tracey Roberts, Olivia Coughlin, Antimicrobial Agents and Chemotherapy	2017	63
Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies Tracey Roberts, John F. Kokai‐Kun, Olivia Coughlin, Clinical Drug Investigation Antimicrobial SusceptibilityAntimicrobial StewardshipAntibioticsMedicinePharmacology	2016	30
Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow‐fill‐seal device in adults: a randomized, active‐controlled study<b>*</b> Eric Sheldon, Robert Jeanfreau, Joseph Sliman, Influenza and Other Respiratory Viruses	2012	15
Outbreak of Acute Respiratory Disease Caused by <i>Mycoplasma pneumoniae</i> on Board a Deployed U.S. Navy Ship Joseph Sliman, David Metzgar, David C. Asseff, Journal of Clinical Microbiology Emerging Infectious DiseasesRespiratory DiseasesMycoplasma PneumoniaeAcute Respiratory DiseaseHealthcare-associated Infection	2009	11

Page 1